Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Journal of Clinical Medicine · 03.03.2026 · 15 (5) · 1919
DOI: 10.3390/jcm15051919 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Clinical Medicine, online erschienen am 03.03.2026. Verfasst von Lokman H Tanriverdi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Pharmacology, Faculty of Medicine, İnönü University, Malatya 44100, Türkiye. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: İnönü University Scientific Research Projects Unit.
Abstract (Originalsprache)
Background/Objectives: There are conflicting results on the effects of ferric derisomaltose (FDM) vs. iron sucrose (IS) for treatment of iron deficiency anemia (IDA). We systematically assessed the efficacy and safety of these treatments.
Methods
We searched Ovid MEDLINE, Web of Science, Pubmed, and Cochrane Central for randomized controlled trials (RCTs) comparing the efficacy and/or safety of FDM vs. IS in patients with IDA. The primary efficacy outcome was the change in hemoglobin (Hb) levels at week 4, and the safety outcome was serious or severe hypersensitivity reactions, as defined by a standardized set of Medical Dictionary for Regulatory Activities (MedDRA) terms. Inverse-variance random effects models were used for meta-analyses.
Results
Five RCTs were included: two in general IDA (n = 1994), two in non-dialysis chronic kidney disease (n = 1542), and one in hemodialysis patients (n = 344). The evidence was very uncertain about the effect of FDM vs. IS for Hb change at week 4 (mean difference [MD] 0.09 g/dL, 95% CI −0.33 to 0.52; I2 = 84%, very low CoE), serious or severe hypersensitivity reactions (MedDRA A + B + C + D, relative risk [RR] 0.83, 95% CI 0.25 to 2.68; I2 = 0%, very low CoE), Hb change at week 8 (MD 0.04 g/dL, 95% CI −0.08 to 0.15; I2 = 0%, very low CoE), Hb increase of ≥2 g/dL at week 4 (RR 1.16, 95% CI 0.97 to 1.38; I2 = 70%, very low CoE), and anaphylactic reactions (MedDRA A, RR 0.38, 95% CI 0.08 to 1.72; I2 = 0%, very low CoE).
Conclusions
We found that FDM vs. IS had little to no effect on outcomes for the treatment of IDA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Pharmacology, Faculty of Medicine, İnönü University, Malatya 44100, Türkiye.
- Division of Hematology, Faculty of Medicine, İnönü University, Malatya 44100, Türkiye.
- Department of Internal Medicine, Faculty of Medicine, Stony Brook University, Stony Brook, NY 11794, USA.
- Health Outcomes, Policy, and Evidence Synthesis (HOPES) Group, University of Connecticut School of Pharmacy, Storrs, CT 06269, USA.
- Unidad de Revisiones Sistemáticas y Meta-Análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola (USIL), Lima 15024, Peru.
ORCID-Profile: Lokman H Tanriverdi, Ahmet Sarici, Adrian V Hernandez
Förderung
- İnönü University Scientific Research Projects Unit
Zitieren
APA
Tanriverdi, L. H., Sarici, A., Aksan, F., & Hernandez, A. V. (2026). Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 15(5), 1919. https://doi.org/10.3390/jcm15051919
Vancouver
Tanriverdi LH, Sarici A, Aksan F, Hernandez AV. Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine. 2026;15(5):1919. doi:10.3390/jcm15051919
BibTeX
@article{Tanriverdi2026,
author = {Tanriverdi, Lokman H and Sarici, Ahmet and Aksan, Feyzullah and Hernandez, Adrian V},
title = {Ferric Derisomaltose Compared to Iron Sucrose in Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {5},
pages = {1919},
doi = {10.3390/jcm15051919}
}
EUVIMED